0000000000418194

AUTHOR

Marfia Girolama Alessandra

showing 2 related works from this author

PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multice…

2021

none 38 no BACKGROUND: Natalizumab (NTZ) is an effective treatment for relapsing-remitting multiple sclerosis (RRMS). However, patients and physicians may consider discontinuing NTZ therapy due to safety or efficacy issues. The aim of our study was to evaluate the NTZ discontinuation rate and reasons of discontinuation in a large Italian population of RRMS patients. MATERIALS AND METHODS: The data were extracted from the Italian MS registry in May 2018 and were collected from 51,845 patients in 69 Italian multiple sclerosis centers. MS patients with at least one NTZ infusion in the period between June 1st 2012 to May 15th 2018 were included. Discontinuation rates at each time point were cal…

Adultmedicine.medical_specialtyDiscontinuation rateNeurologyReasons for discontinuationPopulationProgressive MultifocalRelapsing-RemittingSettore MED/26Multiple sclerosis03 medical and health sciences0302 clinical medicineNatalizumabMultiple Sclerosis Relapsing-RemittingLeukoencephalopathyInternal medicineparasitic diseasesmedicineEffective treatmentHumansImmunologic FactorsMultiple sclerosi030212 general & internal medicineeducationRetrospective Studieseducation.field_of_studyDiscontinuation rate; Multiple sclerosis; Natalizumab; Reasons for discontinuation; Adult; Female; Humans; Immunologic Factors; Middle Aged; Natalizumab; Retrospective Studies; Leukoencephalopathy Progressive Multifocal; Multiple Sclerosis; Multiple Sclerosis Relapsing-Remittingbusiness.industryMultiple sclerosisProgressive multifocal leukoencephalopathyNatalizumabLeukoencephalopathy Progressive MultifocalRetrospective cohort studyMiddle Agedmedicine.diseaseDiscontinuationNeurologySettore MED/26 - NeurologiaFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drug
researchProduct

Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database

2019

ObjectivesA few variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been described, but their frequency and evolution to typical CIDP remain unclear. To determine the frequency and characteristics of the CIDP variants, their possible evolution to typical CIDP, and treatment response.MethodsWe applied a set of diagnostic criteria to 460 patients included in a database of Italian patients with CIDP. Clinical characteristics and treatment response were reviewed for each patient. The Kaplan-Meier curve was used to estimate the progression rate from atypical to typical CIDP.ResultsAt the time of inclusion, 376 (82%) patients had a diagnosis of typical CIDP while 84 …

AdultMaleTreatment responselewis-sumner syndromeAdolescentDatabases FactualDisease durationchronic inflammatory demyelinating polyradiculoneuropathy; CIDP; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis-sumner syndrome; Surgery; Neurology (clinical); Psychiatry and Mental HealthKaplan-Meier EstimateCIDPcomputer.software_genreDisease courseYoung Adultlewis–sumner syndrome03 medical and health sciences0302 clinical medicineHumansMedicineIn patientChildAgedRetrospective StudiesAged 80 and overchronic inflammatory demyelinating polyradiculoneuropathyRetrospective reviewdistal acquired demyelinating symmetric neuropathyDatabasebusiness.industryPolyradiculoneuropathyMiddle Agedchronic inflammatory demyelinating polyradiculoneuropathy; CIDP; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis-sumner syndromemedicine.diseasePsychiatry and Mental healthchronic inflammatory demyelinating polyradiculoneuropathy; CIDP; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis-sumner syndrome; surgery; neurology ; psychiatry and mental healthItalyPolyradiculoneuropathy Chronic Inflammatory Demyelinatingdiagnostic criteriaDisease ProgressionFemaleSettore MED/26 - NeurologiaSurgeryProgression rateNeurology (clinical)CIDP; chronic inflammatory demyelinating polyradiculoneuropathy; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis–sumner syndromebusinesscomputer030217 neurology & neurosurgeryJournal of Neurology, Neurosurgery & Psychiatry
researchProduct